What is Orig3n?
Orig3n operates at the vanguard of personalized medicine, providing a dual-platform approach that combines direct-to-consumer genetic testing with breakthrough cell therapy research. Since its inception in 2014, the company has cultivated the largest suite of lifestyle-related genetic tests on the market, empowering individuals to make data-driven decisions regarding their health and well-being. Simultaneously, the firm leverages its comprehensive cell bank to develop innovative therapies aimed at tissue repair and disease treatment. This integrated business model allows Orig3n to capture value across both the diagnostic and therapeutic segments of the healthcare industry, effectively disrupting traditional medical paradigms through high-throughput biological data analysis and cutting-edge cellular science.
How much funding has Orig3n raised?
Orig3n has raised a total of $50.4M across 5 funding rounds:
Private Equity
$3.1M
Series A
$12.5M
Private Equity
$20M
Series B
$14.4M
Debt
$350K
Private Equity (2015): $3.1M with participation from KTB Network, Mountain Group Partners, Harris & Harris Group, and Hatteras Venture Partners
Series A (2015): $12.5M, investors not publicly disclosed
Private Equity (2017): $20M supported by LabCorp, MGC Venture Partners, DEFTA Partners, KTB-KORUS Fund, Syno Capital, 180 Degree Capital, Spectrum Health Ventures, and Hatteras Venture Partners
Series B (2018): $14.4M featuring 180 Degree Capital, Spectrum Health Ventures, Vectr Ventures, Hatteras Venture Partners, Haitong International Securities Group, LabCorp, DEFTA Partners, and Mountain Group Partners
Debt (2020): $350K backed by PPP
Key Investors in Orig3n
Hatteras Venture Partners
A venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors, providing strategic support and capital to advance human medicine.
LabCorp
A global laboratory services company providing vital diagnostic information and biopharma laboratory services to help healthcare providers and patients make confident medical decisions.
DEFTA Partners
A global venture investment leader focusing on innovative technologies in healthcare and information communication technology to enhance global health outcomes.
What's next for Orig3n?
With the support of major institutional backers, Orig3n is poised to accelerate its clinical development programs and expand its diagnostic reach. The current funding context suggests a transition toward commercializing its regenerative medicine pipeline while refining its consumer genetic offerings. Future strategic initiatives will likely focus on deepening partnerships with healthcare providers and pharmaceutical entities to integrate its proprietary cellular data into broader clinical workflows. As the company matures, the focus will shift from initial market penetration to establishing long-term therapeutic efficacy and scaling its cell banking infrastructure to meet the growing demand for personalized medical solutions.
See full Orig3n company page
